Isodiol International Inc., a leading cannabidiol (CBD) innovator, is well on the road to global expansion. It has just announced the acquisition of strategic assets in the United Kingdom (UK), Brazil, and China. The company has also expanded its international management team and has started developing a state-of-the-art processing facility in China. The new facility will extract cannabinoids and terpenes from certified organic hemp.
The details of the acquisitions are as follows:
BSPG Laboratories Limited
Based in the UK, BSPG is the largest industrial source of hemp extractions worldwide. Isodiol has acquired 100% of the company and will have complete access to BSPG’s exclusive technologies and processes to extract hemp. BSPG also owns an operating facility that refines the CBD molecule to a purity of 99.5% – which means it is highly bioactive and does not contain the high-inducing ingredient called tetrahydrocannabinol (THC).
The total worth of the deal is $13 million. Isodiol has already paid $4.5 million and will pay the remaining $8.5 million over the next 16 months. The company will make additional milestone payments of $25 million when BSPG receives government approval for an active pharmaceutical ingredient (API) that can be sold to pharmaceutical companies worldwide.
Purodiol Do Brasil Ltda
Purodiol Do Brasil or PUR-Brazil supplies Purodiol pharmaceutical products to patients in Brazil and is currently involved a number of clinical studies and trials. It sells products that comply with the regulations of ANVISA (a Brazilian health regulatory agency).
Isodiol has acquired 99% of PUR-Brazil for $2 million in cash and $3 million in common stock. The acquisition will help Isodiol expand its customer base in South America and hence increase revenue.
Processing Patents from Hankang (Yunnan) Biotech Co., Ltd.
Hankang Biotech is based in China and extracts and exports CBD globally. It is also actively working in the research and development sphere for CBD.
Isodiol has purchased three patents to buy and extract CBD from Hankang. It has also signed an exclusive off-take agreement for 100% of Hankang’s CBD production. The total value for the acquisition of patents and the off-take deal is $500,000 in cash.
Isodiol is expecting a substantial increase in global revenue due to these developments. “These transactions mark major milestones for Isodiol. The acquisitions ensure the company has continued source of CBD and scalability of production as our international expansion continues to generate additional market demand for our products. The addition of the intellectual property and likelihood of obtaining an approved active pharmaceutical ingredient designation will ensure that the company holds its position as the world’s leading purveyor of CBD,” said CEO of Isodiol, Marcos Agramont.